<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059264</url>
  </required_header>
  <id_info>
    <org_study_id>HM20014211</org_study_id>
    <nct_id>NCT03059264</nct_id>
  </id_info>
  <brief_title>Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy</brief_title>
  <acronym>TREAT_CDM</acronym>
  <official_title>Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neuromuscular Omnicomprehensive Clinical Center, Milan Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada, Children's Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused&#xD;
      by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn&#xD;
      increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children&#xD;
      with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding&#xD;
      difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As&#xD;
      children grow, they are at risk for intellectual impairment, autistic features,&#xD;
      gastrointestinal symptoms, and motor delay.&#xD;
&#xD;
      The investigators will enroll children with CDM between ages 0-15 with visits at baseline and&#xD;
      one year to evaluate appropriate physical functional outcomes, cognitive function and quality&#xD;
      of life over time. Functional outcome measures will be correlated with potential biomarkers&#xD;
      in the children. Completion of these specific aims will extend the understanding of disease&#xD;
      progression in CDM and will provide the requisite information for successful therapeutic&#xD;
      trials in children with DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>1 year</time_frame>
    <description>Measure of force generated by hand grip</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Congenital and Childhood Onset Myotonic Dystrophy Health Index (CCMDHI)</measure>
    <time_frame>1 year</time_frame>
    <description>Disease specific patient and parent reported outcome measure of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk</measure>
    <time_frame>1 year</time_frame>
    <description>Assess distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>1 year</time_frame>
    <description>An 86-item parent/caregiver-proxy and teacher-proxy rating form of executive function skills in every-day settings such as school, home, and social situations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lip Force</measure>
    <time_frame>1 year</time_frame>
    <description>Measure of force generation by orbicularis oris</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Congenital Myotonic Dystrophy</condition>
  <arm_group>
    <arm_group_label>CDM</arm_group_label>
    <description>Children with Congenital Myotonic Dystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy Children</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural history</intervention_name>
    <description>Longitudinal disease progression</description>
    <arm_group_label>CDM</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study proposes a longitudinal evaluation of 100 children with CDM and 50 healthy&#xD;
        controls, stratified into the following age cohorts: 0-2 years, 11 months; 3 years to 6&#xD;
        years, 11 months; and 7 years and older. The age cohorts are created to ensure an even&#xD;
        distribution across all ages.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        CDM Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-15 yrs&#xD;
&#xD;
          -  Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide&#xD;
             repeats.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other non-DM1 illness that would interfere with the ability or results of the&#xD;
             study in the opinion of site investigator&#xD;
&#xD;
          -  Significant trauma within one month&#xD;
&#xD;
          -  Internal metal or devices&#xD;
&#xD;
        Control Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-15 yrs&#xD;
&#xD;
          -  Healthy children on no medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any illness or situation that, in the opinion of the site investigator, has the&#xD;
             possibility to interfere with study procedures&#xD;
&#xD;
          -  DM type 1 and 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Johnson, MD</last_name>
    <phone>804-552-0014</phone>
    <email>nicholas.johnson@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brittney A Holmberg</last_name>
    <phone>804-552-0014</phone>
    <email>brittney.holmberg@vcuhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodie Howell, LPN</last_name>
      <phone>804-592-1859</phone>
      <email>jodie.howell@vcuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Brittney Holmberg</last_name>
      <phone>804-552-0014</phone>
      <email>brittney.holmberg@vcuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas E Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Neuromuscular Research, Children's Hospital - LHSC</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Ceballos</last_name>
      <email>Delia.CeballosSaenz@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Clinico Nemo</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Mauro</last_name>
      <email>luca.mauro@centrocliniconemo.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandra Di Bari</last_name>
      <email>alessandra.dibari@centrocliniconemo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Valeria Sansone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

